[Benign prostatic hypertrophy: criteria and results].
CLINICAL AND ECONOMICAL SETTING: Benign prostatic adenoma, a commonly observed tumor in older men, is a major public health problem. The economic implications and the multiplicity of therapeutic alternatives require the development of criteria for assessing the effects of proposed treatments. PROSTATE EXPLORATIONS: Two categories of criteria should be determined. Firstly, objective data should be obtained on urine flow rate, post-mictional residue, prostate morphometrics and prostate specific antigen (PSA) levels. Secondly, subjective assessment is needed to determine the extent of the mictional disorder; the international prostatic symptomatic score (IPSS) is an accepted tool used world-wide. Rigorous methodology is indispensable to improve the diagnostic and therapeutic armamentarium and achieve a better cost/benefit ratio for the management of benign prostatic hyperplasia.